IN2015DN02601A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02601A
IN2015DN02601A IN2601DEN2015A IN2015DN02601A IN 2015DN02601 A IN2015DN02601 A IN 2015DN02601A IN 2601DEN2015 A IN2601DEN2015 A IN 2601DEN2015A IN 2015DN02601 A IN2015DN02601 A IN 2015DN02601A
Authority
IN
India
Prior art keywords
present
dabigatran etexilate
preparation
hydrobromide salt
crystalline form
Prior art date
Application number
Other languages
English (en)
Inventor
Anandam Vempali
Sudhir Singh Sanwal
Balaguru Murugesan
Swargam Sathyanarayana
Rajesh Kumar Thaper
Mohan Prasad
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN2601DEN2015 priority Critical patent/IN2015DN02601A/en
Publication of IN2015DN02601A publication Critical patent/IN2015DN02601A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2601DEN2015 2012-09-28 2013-09-30 IN2015DN02601A (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2601DEN2015 IN2015DN02601A (de) 2012-09-28 2013-09-30

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3067DE2012 2012-09-28
PCT/IB2013/059017 WO2014049586A2 (en) 2012-09-28 2013-09-30 Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
IN2601DEN2015 IN2015DN02601A (de) 2012-09-28 2013-09-30

Publications (1)

Publication Number Publication Date
IN2015DN02601A true IN2015DN02601A (de) 2015-09-18

Family

ID=49765595

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2601DEN2015 IN2015DN02601A (de) 2012-09-28 2013-09-30

Country Status (5)

Country Link
US (1) US20150225370A1 (de)
EP (1) EP2900652A2 (de)
CA (1) CA2886094A1 (de)
IN (1) IN2015DN02601A (de)
WO (1) WO2014049586A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108947966A (zh) * 2014-04-04 2018-12-07 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
CN103965164A (zh) * 2014-05-13 2014-08-06 南京生命能科技开发有限公司 甲磺酸达比加群酯的晶体ⅵ及其制备方法
CN103951654B (zh) * 2014-05-13 2016-08-24 南京生命能科技开发有限公司 甲磺酸达比加群酯的晶体v及其制备方法
CN105348260A (zh) * 2014-08-19 2016-02-24 天津药物研究院 达比加群酯氢溴酸盐及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
NZ535663A (en) 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
EP2074112A1 (de) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologisch akzeptable salze aus 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäureethylester
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
CA2734804A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
CA2734809A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy
EA201100358A1 (ru) * 2008-08-19 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Дабигатран для чрескожной хирургической катетеризации сердца
HUP1000069A2 (en) 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
EA201201263A1 (ru) 2010-03-08 2013-04-30 Рациофарм Гмбх Фармацевтическая композиция, содержащая этексилат дабигатрана
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
ES2550771T3 (es) 2010-09-27 2015-11-12 Ratiopharm Gmbh Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法

Also Published As

Publication number Publication date
US20150225370A1 (en) 2015-08-13
WO2014049586A3 (en) 2014-05-15
WO2014049586A2 (en) 2014-04-03
EP2900652A2 (de) 2015-08-05
CA2886094A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
SG10201808624VA (en) Polymorphs of selinexor
TW201613872A (en) IRAK4 inhibiting agents
IN2014MN02598A (de)
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
EA201290726A1 (ru) Новые соли для получения фармацевтических композиций
EA201490919A1 (ru) Производные бетулина
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
IN2015DN02616A (de)
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
WO2013111163A3 (en) Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MY183123A (en) Synthesis of copanlisib and its di hydrochloride salt
IN2014DN06964A (de)
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
IN2015DN02601A (de)
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
IN2014DN09451A (de)
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
IN2015DN01414A (de)
IN2013MU03565A (de)